Gracell Biotechnologies Inc. (NASDAQ:GRCL – Get Rating) – Investment analysts at HC Wainwright issued their Q1 2023 earnings per share (EPS) estimates for Gracell Biotechnologies in a research report issued to clients and investors on Monday, March 13th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.31) for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Gracell Biotechnologies’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Gracell Biotechnologies’ Q2 2023 earnings at ($0.39) EPS, Q4 2023 earnings at ($0.47) EPS, FY2023 earnings at ($1.62) EPS, FY2024 earnings at ($1.53) EPS, FY2025 earnings at ($1.37) EPS, FY2026 earnings at ($1.00) EPS and FY2027 earnings at ($0.46) EPS.
Gracell Biotechnologies Stock Performance
Gracell Biotechnologies stock opened at $2.00 on Thursday. The company has a market cap of $135.36 million, a price-to-earnings ratio of -1.48 and a beta of -1.84. Gracell Biotechnologies has a 12 month low of $1.68 and a 12 month high of $5.69. The company has a debt-to-equity ratio of 0.03, a current ratio of 6.77 and a quick ratio of 6.77. The stock’s 50-day moving average is $2.11 and its 200-day moving average is $2.60.
Institutional Trading of Gracell Biotechnologies
Gracell Biotechnologies Company Profile
Gracell Biotechnologies Inc, a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia.
- Get a free copy of the StockNews.com research report on Gracell Biotechnologies (GRCL)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Gracell Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gracell Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.